Angiotensin 1/2 (2-7): Precision Peptide for Blood Pressure & RAS Research

Executive Summary: Angiotensin 1/2 (2-7) is a synthetic peptide fragment (sequence: ARG-VAL-TYR-ILE-HIS-PRO) derived from angiotensin I and II, playing a pivotal role in the renin-angiotensin system (RAS) and blood pressure regulation (Oliveira et al., 2025). It modulates aldosterone secretion and sodium retention in the distal nephron, directly impacting vasoconstriction and fluid balance. This fragment is produced via enzymatic cleavage, is highly soluble in water, ethanol, and DMSO, and maintains 99.80% purity, as confirmed by HPLC and mass spectrometry (APExBIO). Its biological activity and stability make it a preferred tool for hypertension and cardiovascular disease models. Recent evidence links shorter angiotensin peptides, including (2-7), to modulation of viral spike protein-receptor binding, highlighting new avenues for infectious disease research (Oliveira et al., 2025).

Biological Rationale

Angiotensin 1/2 (2-7) is a naturally occurring peptide fragment derived from the N-terminal region of angiotensin I and II. It is generated by the action of renin and angiotensin-converting enzyme (ACE) within the classical RAS pathway (Oliveira et al., 2025). The peptide sequence—ARG-VAL-TYR-ILE-HIS-PRO—corresponds to amino acids 2 through 7 of the angiotensin precursor. This region is critical for modulating vascular tone, sodium homeostasis, and fluid balance. Angiotensin 1/2 (2-7) exerts its biological effects through receptor-mediated pathways, influencing aldosterone release and promoting sodium reabsorption in the kidney's distal nephron. These actions directly affect arterial blood pressure and vascular resistance, making this peptide fragment a fundamental tool in cardiovascular and renal research. The product, supplied as a highly pure solid by APExBIO, is validated for research use and not for human therapeutic applications (APExBIO).

Mechanism of Action of Angiotensin 1/2 (2-7)

Angiotensin 1/2 (2-7) operates as a functional intermediate in the RAS cascade. Enzymatic cleavage by renin converts angiotensinogen to angiotensin I (1–10), followed by ACE-mediated conversion to angiotensin II (1–8). Subsequent peptidase activity yields shorter fragments, including (2-7) (Oliveira et al., 2025). The (2-7) fragment retains key residues for receptor interaction, especially at the N-terminal arginine and central tyrosine. It modulates vascular smooth muscle contraction primarily through AT1R and AT2R signaling, influencing downstream pathways such as aldosterone secretion, sodium retention, and blood pressure elevation. Notably, recent studies demonstrate that N-terminally truncated angiotensin peptides, including (2-7), can enhance viral spike protein binding to cellular receptors, implicating broader relevance in viral pathogenesis research (Oliveira et al., 2025).

Evidence & Benchmarks

• Angiotensin 1/2 (2-7) enhances spike protein binding to AXL receptor by more than two-fold in antibody-based binding assays, compared to control (Oliveira et al., 2025).
• Shorter N-terminal angiotensin peptides, including (2-7), exhibit stronger enhancement of spike–AXL binding than longer or intact peptides (Oliveira et al., 2025).
• Angiotensin 1/2 (2-7) is confirmed at >99.80% purity by HPLC and mass spectrometry in APExBIO's A1050 lot (APExBIO).
• Solubility benchmarks: ≥46.6 mg/mL in water, ≥2.78 mg/mL in ethanol, and ≥78.4 mg/mL in DMSO, at 25°C (APExBIO).
• Storage at -20°C preserves peptide integrity for at least six months; reconstituted solutions should be used within one week (APExBIO).

Applications, Limits & Misconceptions

Angiotensin 1/2 (2-7) serves as a precise tool for dissecting RAS-mediated pathways in cardiovascular, renal, and viral infection models. It is particularly valued in hypertension research, blood pressure regulation assays, and studies investigating peptide-mediated SARS-CoV-2 receptor interactions (Oliveira et al., 2025). The peptide's defined sequence and high purity support reproducible results in mechanistic studies. For comprehensive mechanistic discussions, see this article, which is extended here with new viral pathogenesis findings. For translational guidance, Pepbridge.net's review is updated by this dossier with recent peer-reviewed evidence on spike-protein interactions. Additionally, this overview is clarified with precise solubility and storage benchmarks.

Common Pitfalls or Misconceptions

• Angiotensin 1/2 (2-7) is not approved for diagnostic or therapeutic use; it is for research applications only (APExBIO).
• The peptide does not act as a full agonist for all angiotensin receptors—its activity profile is fragment-specific.
• It should not be used as a substitute for intact angiotensin II in physiological assays requiring full sequence-dependent effects.
• Long-term storage in solution may compromise peptide integrity; short-term use is strongly recommended.
• Assay conditions such as buffer, temperature, and pH must be optimized; solubility varies significantly across solvents.

Workflow Integration & Parameters

Angiotensin 1/2 (2-7) is supplied as a solid with a molecular weight of 783.92 Da and formula C37H57N11O8 (APExBIO). For most in vitro experiments, reconstitute in water or DMSO to a working concentration between 10–100 μM. Mix gently and avoid repeated freeze-thaw cycles. Store remaining aliquots at -20°C. For binding or vasoconstriction assays, dilute in physiological buffer (e.g., PBS, pH 7.4). Confirm peptide integrity by analytical HPLC before use in critical experiments. For infectious disease modeling, pre-incubate peptide with target cells or receptor proteins under defined conditions (e.g., 37°C, 1 hour) as described in recent SARS-CoV-2 spike binding studies (Oliveira et al., 2025).

Conclusion & Outlook

Angiotensin 1/2 (2-7) stands as a validated, high-purity research tool for dissecting RAS biology, cardiovascular regulation, and viral pathogenesis mechanisms. Its sequence specificity and robust solubility profile support precision workflows in hypertension and infectious disease modeling. As evidence mounts for peptide-mediated modulation of viral receptor binding, this fragment will likely remain central to translational research in both vascular and emerging infectious diseases. For product details or ordering, refer to the Angiotensin 1/2 (2-7) A1050 product page.